All filters
Abstracts
Drug effect of clofazimine on persistent mycobacteria explain an unexpected increase of bacterial load in patients
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Stratified dosage regimens from early bactericidal activity studies: an application to pretomanid
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
A PBPK modelling approach to simulate the rifampicin-moxifloxacin drug-drug interaction in TB patients
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
An assay to measure drug tolerance of M. tuberculosis in the caseous center of pulmonary lesions
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Levofloxacin target attainment analysis in MDR-TB patients: time is ripe for proactive TDM
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Population Pharmacokinetics of Linezolid in TB Patients: Dosing Regimens Simulation and Target Attainment Analysis
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
PK-PD of isoniazid given at different doses among patients with MDR-TB with INH resistance mediated by inhA mutations: modeling results from ACTG A5312.
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Can longitudinal PKPD biomarkers be used to forecast treatment outcome instead of M2 conversion? A population pharmacokinetic-pharmacodynamic analysis in drug sensitive pulmonary tuberculosis.
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
The OptiRIF study: pharmacokinetics of high-dose rifampicin in children
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Exposures to first-line drugs in African and Indian children with drug-susceptible tuberculosis using novel fixed-dose-combination tablets at WHO dosing recommendation in the SHINE trial
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Ethionamide population pharmacokinetic model and Monte Carlo Simulation in patients with multidrug-resistant tuberculosis
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Increased bactericidal activity but dose-limiting tolerability at 50 mg/kg rifampicin
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Pharmacogenetics and pharmacokinetics of first-line anti-tuberculosis drugs in the HIRIF trial
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Pharmacokinetics and Early Bactericidal Activity of Meropenem (with Amoxicillin/Clavulanate), With and Without Rifampicin, for Drug-Susceptible TB
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Co-administration of pretomanid with rifampin or rifabutin among patients with pulmonary TB: interim PK results from “Assessing Pretomanid for Tuberculosis” (APT) trial
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Relationship between plasma and intracellular concentrations of bedaquiline and its M2 metabolite in South African patients with drug-resistant TB
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Evaluating hepatotoxicity of bedaquiline treatment in multi-drug resistant tuberculosis patients
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Videos
Debate: Do Integrase Inhibitors and/or TAF Lead to Weight Gain? - Dr. Jürgen Rockstroh Con Standpoint -
Presented at:
Central and Eastern European Meeting on Viral Hepatitis and HIV 2020
Videos
Long-Acting Therapies: Which Patients Will Benefit Most? - Sharon Walmsley
Presented at:
Central and Eastern European Meeting on Viral Hepatitis and HIV 2020
Videos
HIV and COVID-19 co-infection: An update - Dr. Cristiana Oprea
Presented at:
Central and Eastern European Meeting on Viral Hepatitis and HIV 2020
Videos
Abstract #7 - Development of structural changes in patients treated for VHC in the Czech Republic from viewpoint of stage of liver fibrosis, HCV genotype, age and treatment strategy - Viktor Aster, Charles University, Czech Republic
Presented at:
Central and Eastern European Meeting on Viral Hepatitis and HIV 2020
Slidesets
Managing Highly Treatment-Experienced Patients - Prof. Anca Streinu Cercel -
Presented at:
Central and Eastern European Meeting on Viral Hepatitis and HIV 2020
Slidesets
The Acute HCV Epidemic in MSM: What Have We Learned Thus Far? Christoph Boesecke
Presented at:
Central and Eastern European Meeting on Viral Hepatitis and HIV 2020
Slidesets
ART in Women: Which Drugs are Safe and What are the Challenges? - Dr. Annette Haberl
Presented at:
Central and Eastern European Meeting on Viral Hepatitis and HIV 2020